Inhibition of inflammation mediates the protective effect of atorvastatin reload in patients with coronary artery disease undergoing noncardiac emergency surgery

Qu, Yang; Wei, Lixin; Zhang, Haiqing

doi:10.1097/mca.0000000000000143

Cited by 8 publications

(2 citation statements)

References 29 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previously published studies highlight the absence of an association between polyunsaturated fatty acid and adiponectin in patients in secondary prevention for CVD [ 43 , 44 ]. Why some studies have not found this association is not clear, but it seems to be linked to the fact that these patients are well medicated with drugs that may affect inflammatory biomarker activities [ 45 , 46 ].…”

Section: Discussionmentioning

confidence: 99%

Association between plasma fatty acids and inflammatory markers in patients with and without insulin resistance and in secondary prevention of cardiovascular disease, a cross-sectional study

Bersch-Ferreira

Sampaio

Gehringer

et al. 2018

Nutr J

View full text Add to dashboard Cite

BackgroundProinflammatory biomarkers levels are increased among patients with cardiovascular disease, and it is known that both the presence of insulin resistance and diet may influence those levels. However, these associations are not well studied among patients with established cardiovascular disease. Our objective is to compare inflammatory biomarker levels among cardiovascular disease secondary prevention patients with and without insulin resistance, and to evaluate if there is any association between plasma fatty acid levels and inflammatory biomarker levels among them.MethodsIn this cross-sectional sub-study from the BALANCE Program Trial, we collected data from 359 patients with established cardiovascular disease. Plasma fatty acids and inflammatory biomarkers (interleukin (IL)-1β, IL-6, IL-8, IL-10, IL-12, high sensitive C-reactive protein (hs-CRP), adiponectin, and tumor necrosis factor (TNF)-alpha) were measured. Biomarkers and plasma fatty acid levels of subjects across insulin resistant and not insulin resistant groups were compared, and general linear models were used to examine the association between plasma fatty acids and inflammatory biomarkers.ResultsSubjects with insulin resistance had a higher concentration of hs-CRP (p = 0.002) and IL-6 (p = 0.002) than subjects without insulin resistance. Among subjects without insulin resistance there was a positive association between stearic fatty acid and IL-6 (p = 0.032), and a negative association between alpha-linolenic fatty acid and pro-inflammatory biomarkers (p < 0.05). Among those with insulin resistance there was a positive association between monounsaturated fatty acids and arachidonic fatty acid and adiponectin (p < 0.05), and a negative association between monounsaturated and polyunsaturated fatty acids and pro-inflammatory biomarkers (p < 0.05), as well as a negative association between polyunsaturated fatty acids and adiponectin (p < 0.05). Our study has not found any association between hs-CRP and plasma fatty acids.ConclusionsSubjects in secondary prevention for cardiovascular disease with insulin resistance have a higher concentration of hs-CRP and IL-6 than individuals without insulin resistance, and these inflammatory biomarkers are positively associated with saturated fatty acids and negatively associated with unsaturated fatty acids.Electronic supplementary materialThe online version of this article (10.1186/s12937-018-0342-1) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Association between plasma fatty acids and inflammatory markers in patients with and without insulin resistance and in secondary prevention of cardiovascular disease, a cross-sectional study

Bersch-Ferreira

Sampaio

Gehringer

et al. 2018

Nutr J

View full text Add to dashboard Cite

show abstract

“…Еще более выра-женный эффект был показан в подгруппе пациентов с СД 2 типа [29]. В исследовании Qu Y, et al [30], было показано влияние больших доз аторвастатина не только на уровень вч-СРБ, но и на уровень другого маркера воспаления -интерлейкина-6 (IL-6). Назна-чение 80 мг аторвастатина перед некардиальным опе-ративным вмешательством пациентам со стабиль-ными формами ИБС, с последующим приемом препа-рата в послеоперационном периоде, привело к снижению уровня вч-СРБ на 30,4% от исходного уровня в группе аторвастатина и только на 17,4% в группе контроля; уровень IL-6 также снижался достоверно в группе аторвастатина: 30,9% и 19,7% от исходного уровня (p<0,001 в обоих случаях).…”

Section: влияние на маркеры воспаленияunclassified

Atorvastatin — 20 Years in the Struggle for Life

Gogolashvili¹

2018

Russ J Cardiol

View full text Add to dashboard Cite

Pharmacological treatment of vascular risk factors for reducing mortality and cardiovascular events in patients with abdominal aortic aneurysm

Robertson

Atallah

Stansby

2017

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

Inhibition of inflammation mediates the protective effect of atorvastatin reload in patients with coronary artery disease undergoing noncardiac emergency surgery

Abstract: Atorvastatin reload may improve the clinical outcome of patients with stable CAD undergoing noncardiac emergency surgery by decreasing the incidence of AHF and MACE during hospitalization. The mechanism of this protective effect may involve inhibition of inflammation.

Cited by 8 publications

References 29 publications

Association between plasma fatty acids and inflammatory markers in patients with and without insulin resistance and in secondary prevention of cardiovascular disease, a cross-sectional study

Association between plasma fatty acids and inflammatory markers in patients with and without insulin resistance and in secondary prevention of cardiovascular disease, a cross-sectional study

Atorvastatin — 20 Years in the Struggle for Life

Pharmacological treatment of vascular risk factors for reducing mortality and cardiovascular events in patients with abdominal aortic aneurysm

Contact Info

Product

Resources

About